Reckitt clears way for GSK to buy Pfizer's consumer healthcare unit after ending talks
“An acquisition for the whole Pfizer consumer health business did not fit our acquisition criteria," said Reckitt boss Rakesh Kapoor
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 26 of 38
Investments and investor services
FTSE 100 plunges 1.23% to below 7,000 after BoE rate decision
In the currency markets, the pound is up 0.13% against the Euro, but down 0.20% against the US dollar.
Hikma Pharmaceuticals and Vectura hit by US regulatory setback
Hikma hit a roadblock with the US Food & Drug Administration as it lodged an abbreviated new drug application for asthma treatment Advair Diskus, first developed by GlaxoSmithKline
Investments and investor services
FTSE 100 closes in red, despite US market turnaround
In London, the FTSE 100 closed down around 29 points at 7,252
Archive
Another day, another bank reporting results - Barclays the next up to the oche
Day ahead includes a swathe of FTSE 100 results, including from the likes of Barclays PLC, British American Tobacco PLC, BAE Systems PLC, and Centrica PLC
Reckitt Benckiser's bid to buy Pfizer unit a step in the right direction, says JP Morgan
Shares in Reckitt have continued to decline after Monday's disappointing results as JP Morgan cut its 2018 earnings guidance and target price
Investments and investor services
FTSE 100 makes up some ground to close a tad lower as earnings disappoint
The minister responsible for Britain's exit from the EU, David Davis said the UK would lead a “global race to the top"
Reckitt Benckiser Group expects a return to growth this year
The group returned to like-for-like revenue growth in the fourth quarter..
Archive
Banks to feature strongly in deluge of blue chip earnings, including Lloyds, RBS, Barclays
Week ahead includes a deluge of blue chip results, notably from the banking sector, including numbers from HSBC PLC, Barclays PLC, Lloyds Banking Group PLC, and Royal Bank of Scotland PLC
GlaxoSmithKline winning over City number crunchers
Is the market being too negative about the prospects for the HIV franchise and generic competition to its best-selling asthma treatment, Advair?
GSK sues US rival Gilead Sciences for alleged HIV drug patent infringement
GSK’s one pill, once daily treatment was approved back in November, while Gilead’s drug got the green light from the US FDA on Wednesday
GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler
If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
FTSE 100 closes strongly higher as markets stabilise
The UK blue chip index closed up 138 at 7,279 - above the day’s peak of 7,255.
Archive
Rio Tinto expected to reiterate policy of value over volume
Rio Tinto is expected to carry on returning piles of cash to shareholders but some people think a dividend cut at Glaxo is on the cards
FTSE 100 succumbs to global profit-taking, closes firmly in red
The UK blue chip index closed down 108.45 points at 7.334, which had been the session low
Archive
Bank of England rate decision eyed, plus numbers from blue chips BP and Glaxo in coming week
After November's hike, another UK rate rise is unlikely this month, although some Bank of England MPC members may vote for a rise after a unanimous vote in December
NeuroMetrix booms as it enters into strategic collaboration with healthcare giant GSK
GSK is paying Neurometrix US$5mln up front plus up to US$21.5mln in milestone payments to acquire the exclusive ownership of the Quell technology
Barclays cites progress in HIV and new shingles vaccine as it turns bullish on GSK
Analyst Emmanuel Papadakis has upgraded GSK to ‘overweight’ and hiked his price target to £16.50, claiming that any risks are now priced in, while progress has been made in HIV and shingles
GSK edges higher as it releases “promising” new data from phase I/II blood cancer trial
In the dose expansion phase of its DREAMM-1 phase I/II study of GSK2857916, the antibody-drug conjugate demonstrated a 60% response rate and median progression-free survival of 7.9 months